Literature DB >> 3647047

Clinical evaluation of Abbott and Wellcome enzyme linked immunosorbent assays for detection of serum antibodies to human immunodeficiency virus (HIV).

R P Evans, D C Shanson, P P Mortimer.   

Abstract

Abbott and Wellcome enzyme linked immunosorbent assays (ELISAs) for detection of antibodies to human immunodeficiency virus (HIV) were compared in tests on 932 sera collected predominantly from male homosexuals attending a sexually transmitted disease (STD) clinic in central London. Two hundred and twenty three sera had HIV antibodies detected by both types of assay, with confirmation of the results by further tests carried out at the Virus Reference Laboratory (VRL) in Colindale. There was a 97.3% correlation between the results obtained by the two commercial ELISA assays on the tests carried out on unheated sera. The Abbott ELISA gave significantly more false positive results than the Wellcome test when the manufacturer's instructions for cut off values were followed. There was one false negative Abbott results: it failed to react to repeated Abbott ELISA but was positive by Wellcome and confirmatory assays. Of 283 heat treated sera 14.8% gave falsely reactive results with the Abbott assay whereas there were no differences between heated and unheated sera with the Wellcome assay. VRL or Western blot confirmatory assays, or both, confirmed all the 235 positive results obtained with the Wellcome assay.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3647047      PMCID: PMC1141023          DOI: 10.1136/jcp.40.5.552

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  6 in total

1.  The politics of alcohol.

Authors:  A Paton
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-05

2.  Prevalence of HTLV-III antibody in American blood donors.

Authors:  J B Schorr; A Berkowitz; P D Cumming; A J Katz; S G Sandler
Journal:  N Engl J Med       Date:  1985-08-08       Impact factor: 91.245

3.  Incidence and risk of transmission of HTLV III infections to staff at a London hospital, 1982-85.

Authors:  D C Shanson; R Evans; L Lai
Journal:  J Hosp Infect       Date:  1985-12       Impact factor: 3.926

4.  Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain.

Authors:  R Cheingsong-Popov; R A Weiss; A Dalgleish; R S Tedder; D C Shanson; D J Jeffries; R B Ferns; E M Briggs; I V Weller; S Mitton
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

5.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

6.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.